Drug intelligence / Profile preview

ACP-2127

Development stage: Preclinical
Lead developer: Quest PharmaTech
Modality: Small Molecules
Administration: Oral

Overview

ACP-2127 is an investigational small‑molecule kinase inhibitor described as a dual cyclin‑dependent kinase (CDK) and mechanistic target of rapamycin (mTOR) inhibitor, initially developed by Quest PharmaTech for oncology indications.[1][11] Although detailed target selectivity, structure, and clinical data have not been publicly disclosed, ACP-2127 is characterized in pipeline databases as a preclinical antineoplastic agent aiming to suppress tumor cell proliferation and survival by concomitantly blocking CDK‑driven cell‑cycle progression and mTOR‑mediated growth and metabolic signaling.[1][11]

Targets

CDK (CDK family)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on ACP-2127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACP-2127.

Explore the full profile